Zijiang Enterprise set up a packaging company in Hubei with 20 million yuan. According to the enterprise search APP, Hubei Zijiang Packaging Co., Ltd. was recently established, with Shao Chunjiang as the legal representative and a registered capital of 20 million yuan. Its business scope includes: the production of plastic packaging containers and tools for food; Sales of plastic packaging containers, tools and products for food. Enterprise investigation shows that the company is wholly owned by Zijiang Enterprise.Trump said that he will meet with Amazon founder Bezos next week. US President-elect Trump said on Thursday that he will meet with Amazon founder Bezos next week and stressed that he will continue to contact with technology giants before returning to the White House, including those companies that have signed contracts with the US government. Trump pointed out that he had met with Meta CEO Zuckerberg earlier and had extensive contact with Tesla CEO Musk.Zijiang Enterprise set up a packaging company in Hubei with 20 million yuan. According to the enterprise search APP, Hubei Zijiang Packaging Co., Ltd. was recently established, with Shao Chunjiang as the legal representative and a registered capital of 20 million yuan. Its business scope includes: the production of plastic packaging containers and tools for food; Sales of plastic packaging containers, tools and products for food. Enterprise investigation shows that the company is wholly owned by Zijiang Enterprise.
The scale of A500-related funds exceeded 240 billion yuan, and the scale of CSI A500ETF leader (563,800) jumped to the first place in Shanghai. On December 12, the total scale of funds tracking CSI A500 index reached 242.1 billion yuan, which was the fastest index in the history of A-share. In addition, the CSI A500 Index also contributed about one third of the increase in scale index funds since September. Among them, CSI A500ETF leader (563800) has attracted the most gold since its listing on November 18th, with a net inflow of 14.2 billion yuan, and its latest scale has exceeded 16.5 billion yuan, ranking first in Shanghai.The Ministry of National Defense responded to the question of whether to engage in exercises: the situation is unpredictable, and the leader of the Taiwan Province region, Lai Qingde, recently "transited" Hawaii and Guam. On the morning of December 13th, Senior Colonel Wu Qian, Director of the Information Bureau of the Ministry of National Defense and spokesman of the Ministry of National Defense, answered a reporter's question on whether the PLA would conduct exercises. A: It is the sacred duty of the People's Liberation Army to safeguard national sovereignty and territorial integrity, the fundamental interests of the Chinese nation and the common interests of compatriots on both sides of the strait. Soldiers have no constant potential and water is impermanent. Whether and when to hold the exercise is up to us to decide independently according to our own needs and the struggle situation. No matter whether the exercise is held or not, the PLA will not be absent or soft in fighting for "independence" and promoting reunification. Any act of "seeking independence by relying on foreign countries" and "seeking independence by force" will be severely punished and doomed to failure.Zheshang Securities: It does not rule out the possibility of lowering the RRR and cutting interest rates at the same time before the end of the year. Zheshang Securities research report said that this central economic work conference went further on the basis of the previous Politburo meeting, and clearly put forward "timely RRR reduction and interest rate reduction". Combined with the central bank's statement on the RRR reduction space in late September, it is expected that there will be a 50-basis-point RRR reduction before the end of the year, which will greatly promote interest rate reduction in the first quarter of next year, and even does not rule out the possibility of simultaneous RRR reduction and interest rate reduction before the end of the year. We are optimistic that the equity market and the bond market will step out of the double bull market in the process of gradual policy development.
Good wife set up an intelligent technology company in Quanzhou, and the enterprise search APP shows that Quanzhou Sunguest Intelligent Technology Co., Ltd. was established recently, with the legal representative of Cao Caifeng and the registered capital of 500,000 yuan. Its business scope includes: engineering and technical research and experimental development; Network and information security software development; Software development; Digital technology services, etc. Enterprise equity penetration shows that the company is wholly owned by Haotai.Klarna, a Swedish payment company, said that it stopped recruiting hundreds of employees because of AI during the year. Sebastian Siemiatkowski, CEO of Klarna, a Swedish payment company planning to go public in the US, said that the company stopped recruiting a year ago, mainly because it invested in artificial intelligence (AI), which can replace the work of hundreds of employees in the company. According to Siemiatkowski, the number of employees decreased by 22% to 3,500 within one year, mainly due to brain drain. He pointed out that at present, about 200 employees in the company use artificial intelligence for their core work, and will improve the efficiency of artificial intelligence by accelerating the salary growth of employees.Guojin Securities: The warm wind of medical policy comes first, then the progress of innovation going out to sea, and then the opportunity of performance reversal. Guojin Securities Research Report said that the core investment opportunities in the pharmaceutical sector in 25 years will revolve around three logics: 1) innovation going out to sea; 2) demand recovery; 3) Policy expectation reversal. At present, the policy warm wind comes first (the medical track policy continues to warm up, and the overall industry expectation is expected to be optimistic); Then, R&D and innovation will go to sea (innovative drug track will continue to make progress, and it will still be the hottest track in the pharmaceutical sector in 2025, especially it is recommended to pay attention to the clinical data reading and commercialization progress of the first-line target, as well as the fluctuation opportunity of the expected difference of the second-line innovative drugs), and then the performance growth rate is expected to bottom out in the first half of 2025 (but it will take time for this improvement in performance growth rate to come. Considering the current industry communication and historical base, it is expected that 4Q24 and 1Q25 should still be cautiously optimistic.)
Strategy guide 12-14
Strategy guide
12-14
Strategy guide
12-14
Strategy guide 12-14
Strategy guide
12-14